Cargando…

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice

PURPOSE: As epidermal growth factor receptor (EGFR) inhibitors are associated with a variety of dermatologic adverse events (dAEs), the purpose of this study was to develop an overview of current knowledge of dAEs associated with EGFR inhibitors and to identify knowledge gaps regarding incidence, tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tischer, Bernd, Huber, Renate, Kraemer, Matthias, Lacouture, Mario E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5196015/
https://www.ncbi.nlm.nih.gov/pubmed/27718067
http://dx.doi.org/10.1007/s00520-016-3419-4
_version_ 1782488440511660032
author Tischer, Bernd
Huber, Renate
Kraemer, Matthias
Lacouture, Mario E.
author_facet Tischer, Bernd
Huber, Renate
Kraemer, Matthias
Lacouture, Mario E.
author_sort Tischer, Bernd
collection PubMed
description PURPOSE: As epidermal growth factor receptor (EGFR) inhibitors are associated with a variety of dermatologic adverse events (dAEs), the purpose of this study was to develop an overview of current knowledge of dAEs associated with EGFR inhibitors and to identify knowledge gaps regarding incidence, treatment, impact on quality of life (QOL), and patient acceptance. METHOD: A structured literature search was conducted using MEDLINE/PubMed (January 1983 to January 2014). In total, 71 publications published from 2004 to 2014 were identified for consideration in the final evidence review. RESULTS: The majority of published articles concentrate on the incidence of skin reactions, duration, treatment, and prevention strategies. Different grading systems based on the symptoms of skin rash or on health-related QOL (HRQOL) are used. An additional topic is the possible correlation between acneiform rash and efficacy of EGFR inhibitors. Knowledge gaps identified in the literature were how dAEs impact QOL compared with other AEs from a patient’s perspective, patients’ acceptance of dAEs (willingness to tolerate), and the impact of physician-patient communication on treatment decisions. CONCLUSIONS: Research is needed on the impact of dAEs on patients’ acceptance of cancer treatments. Systematic studies are missing that compare the impact of dAEs with other toxicities on therapy decisions from both physician’s and patient’s view, and that investigate the balance between efficacy and avoidance of acneiform rash in treatment decisions. Such studies could provide deeper insights into the acceptance of the risk of untoward dermatologic events by both physicians and patients when treating advanced cancers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00520-016-3419-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5196015
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-51960152017-01-13 Dermatologic events from EGFR inhibitors: the issue of the missing patient voice Tischer, Bernd Huber, Renate Kraemer, Matthias Lacouture, Mario E. Support Care Cancer Review Article PURPOSE: As epidermal growth factor receptor (EGFR) inhibitors are associated with a variety of dermatologic adverse events (dAEs), the purpose of this study was to develop an overview of current knowledge of dAEs associated with EGFR inhibitors and to identify knowledge gaps regarding incidence, treatment, impact on quality of life (QOL), and patient acceptance. METHOD: A structured literature search was conducted using MEDLINE/PubMed (January 1983 to January 2014). In total, 71 publications published from 2004 to 2014 were identified for consideration in the final evidence review. RESULTS: The majority of published articles concentrate on the incidence of skin reactions, duration, treatment, and prevention strategies. Different grading systems based on the symptoms of skin rash or on health-related QOL (HRQOL) are used. An additional topic is the possible correlation between acneiform rash and efficacy of EGFR inhibitors. Knowledge gaps identified in the literature were how dAEs impact QOL compared with other AEs from a patient’s perspective, patients’ acceptance of dAEs (willingness to tolerate), and the impact of physician-patient communication on treatment decisions. CONCLUSIONS: Research is needed on the impact of dAEs on patients’ acceptance of cancer treatments. Systematic studies are missing that compare the impact of dAEs with other toxicities on therapy decisions from both physician’s and patient’s view, and that investigate the balance between efficacy and avoidance of acneiform rash in treatment decisions. Such studies could provide deeper insights into the acceptance of the risk of untoward dermatologic events by both physicians and patients when treating advanced cancers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00520-016-3419-4) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-10-07 2017 /pmc/articles/PMC5196015/ /pubmed/27718067 http://dx.doi.org/10.1007/s00520-016-3419-4 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Tischer, Bernd
Huber, Renate
Kraemer, Matthias
Lacouture, Mario E.
Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
title Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
title_full Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
title_fullStr Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
title_full_unstemmed Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
title_short Dermatologic events from EGFR inhibitors: the issue of the missing patient voice
title_sort dermatologic events from egfr inhibitors: the issue of the missing patient voice
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5196015/
https://www.ncbi.nlm.nih.gov/pubmed/27718067
http://dx.doi.org/10.1007/s00520-016-3419-4
work_keys_str_mv AT tischerbernd dermatologiceventsfromegfrinhibitorstheissueofthemissingpatientvoice
AT huberrenate dermatologiceventsfromegfrinhibitorstheissueofthemissingpatientvoice
AT kraemermatthias dermatologiceventsfromegfrinhibitorstheissueofthemissingpatientvoice
AT lacouturemarioe dermatologiceventsfromegfrinhibitorstheissueofthemissingpatientvoice